A 5-year sensitivity analysis of a recent trial showed improved efficacy outcomes and toxicity profiles for patients receiving a new adjuvant therapy for HER2-positive breast cancer. READ MORE
A 5-year sensitivity analysis of a recent trial showed improved efficacy outcomes and toxicity profiles for patients receiving a new adjuvant therapy for HER2-positive breast cancer.
Factors predicting HER2 discordance between primary tumor and circulating tumor cells may be used as a surrogate for tumor biology and tumor heterogeneity in patients with breast cancer.
Researchers examined whether low levels of pre-existing cytotoxic tumor-infiltrating lymphocytes can predict the response to antibody- and molecule-based drugs in metastatic HER2-positive breast cancer.
Halting adjuvant endocrine therapy for ER-positive breast cancer after 5 years does not reduce the risk of cancer recurrence in the long-term.
Research in Review
An immuno-agent improves PFS and lowers the risk of death for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation.
A low level of stromal cytotoxic T-cell infiltration in breast cancer tumor specimens predicts patients who may benefit most from antibody- vs molecular-based HER2 inhibitors.
A neoadjuvant chemotherapy combination used to treat breast cancer increases the risk of disease metastasis.
In younger women with hormone receptor-positive breast cancer, ovarian function suppression after surgery drives large improvements in breast cancer-free interval when combined with drug therapy.